Articles with public access mandates - Guillermo Garcia-ManeroLearn more
OverallNIHCPRITCancer Research UKDFGGovernment of SpainV Foundation, USAMRCHHMIBlood Cancer UKGovernment of ItalyNSFCNIHRAIRC Foundation for Cancer Research in ItalyFWFDSTWellcomeSNSFDoDNHMRCFWOFondazione CariploNKFINSFDOEUSEDVAAHAFNRSCIHRCASHelmholtzBanking Foundation "la Caixa"Academy of FinlandSFITelethonFCTVersus Arthritis, UKBBSRCBHFNational Centre for the Replacement, Refinement and Reduction of Animals in Research, UKParkinson's UKSTFCWorldwide Cancer Research, UKEuropean CommissionDoris Duke Charitable FoundationState of CalifoniaPCORIKWF
Not available anywhere: 43
Myelodysplastic syndromes
PL Greenberg, E Attar, JM Bennett, CD Bloomfield, CM De Castro, ...
Journal of the National Comprehensive Cancer Network 9 (1), 30-56, 2011
Mandates: US National Institutes of Health
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ...
The Lancet Haematology 7 (10), e724-e736, 2020
Mandates: US National Institutes of Health
Oncogenic functions of the transcription factor Nrf2
I Gañán-Gómez, Y Wei, H Yang, MC Boyano-Adánez, G García-Manero
Free Radical Biology and Medicine 65, 750-764, 2013
Mandates: Government of Spain
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 …
G Garcia-Manero, P Fenaux, A Al-Kali, MR Baer, MA Sekeres, GJ Roboz, ...
The lancet oncology 17 (4), 496-508, 2016
Mandates: US National Institutes of Health
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
HM Kantarjian, GJ Roboz, PL Kropf, KWL Yee, CL O'Connell, R Tibes, ...
The Lancet Oncology 18 (10), 1317-1326, 2017
Mandates: US National Institutes of Health
Novel drugs for older patients with acute myeloid leukemia
G Montalban-Bravo, G Garcia-Manero
Leukemia 29 (4), 760-769, 2015
Mandates: US National Institutes of Health
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
P Strati, G Tang, DY Duose, S Mallampati, R Luthra, KP Patel, M Hussaini, ...
Leukemia & Lymphoma 59 (7), 1672-1676, 2018
Mandates: US National Institutes of Health
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
U Rozovski, M Ohanian, F Ravandi, G Garcia-Manero, S Faderl, S Pierce, ...
Leukemia & lymphoma 56 (5), 1392-1397, 2015
Mandates: US National Institutes of Health
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia
M Alfayez, GC Issa, KP Patel, F Wang, X Wang, NJ Short, JE Cortes, ...
Leukemia 35 (3), 691-700, 2021
Mandates: US National Institutes of Health
Phase II trial of MEK inhibitor binimetinib (MEK162) in RAS-mutant acute myeloid leukemia
A Maiti, K Naqvi, TM Kadia, G Borthakur, K Takahashi, P Bose, NG Daver, ...
Clinical Lymphoma Myeloma and Leukemia 19 (3), 142-148. e1, 2019
Mandates: US National Institutes of Health
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, ...
Leukemia 32 (1), 241-244, 2018
Mandates: US National Institutes of Health
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
P Bose, S Verstovsek, JE Cortes, S Tse, Y Gasior, N Jain, EJ Jabbour, ...
Leukemia 34 (9), 2489-2492, 2020
Mandates: US National Institutes of Health
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, CD DiNardo, ...
Leukemia 31 (2), 318-324, 2017
Mandates: US National Institutes of Health
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
K Sasaki, HM Kantarjian, S O’Brien, F Ravandi, M Konopleva, ...
International journal of hematology 109, 545-552, 2019
Mandates: US National Institutes of Health
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation
B Oran, RE Champlin, F Wang, T Tanaka, RM Saliba, G Al-Atrash, ...
Leukemia 36 (1), 257-262, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
P Boddu, H Kantarjian, F Ravandi, G Garcia-Manero, G Borthakur, ...
Leukemia & Lymphoma 59 (9), 2238-2241, 2018
Mandates: US National Institutes of Health
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
G Montalban-Bravo, D Hammond, CD DiNardo, M Konopleva, ...
Leukemia 35 (5), 1494-1499, 2021
Mandates: US National Institutes of Health
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
Y Sasaki, HM Kantarjian, NJ Short, F Wang, K Furudate, H Uryu, R Garris, ...
Leukemia 36 (5), 1253-1260, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience
R Assi, H Kantarjian, M Keating, N Pemmaraju, S Verstovsek, ...
Leukemia & Lymphoma 62 (4), 909-917, 2021
Mandates: US National Institutes of Health
Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study
Y Yamamura, R Oum, KY Elhor Gbito, G Garcia-Manero, SS Strom
Nutrition and cancer 65 (8), 1132-1140, 2013
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program